Companies/BioSyent Inc.

Company profile

BioSyent Inc.

OTC: BIOYF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Mississauga, ONReports USD

#497 of 1,394 Healthcare companies by revenue67th-percentile growth

EA Score

83B+

FH 90DQ —GM 69SS 71

v0.1 · 45/100 weight · provisional

↑ return on assets, operating margin · ↓ disclosure history, 3-yr revenue growth

Methodology →

Revenue TTM

$33.3M

Rev growth YoY (TTM)

+21.2%

Net income (FY)

$6.4M

Employees

711

Market cap

$116.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$30.8M43.0M CAD2025

Net income$6.4M9.0M CAD2025

Operating income$8.1M11.3M CAD2025

Total assets$36.0M49.4M CAD2025

Liabilities$5.8M8.0M CAD2025

Equity$30.2M41.4M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$16.6M

FY18

$16.1M

FY19

$16.6M

FY20

$22.8M

FY21

$21.5M

FY22

$23.4M

FY23

$25.6M

FY24

$30.8M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

BioSyent Inc. booked $30.8M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 20.9% net margin.

Peers · Healthcare

OptimizeRx Corp.72B Corbus Pharmaceuticals Holdings, Inc.44D Noveris Health Sciences Inc.——Black Diamond Therapeutics, Inc.60C

Key facts

CEORené C. Goehrum

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersMississauga, ON

ExchangeOTC: BIOYF

Employees711

IPO date2012-02-22

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.